 | • レポートコード：MRC2203A074 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のカルシウムチャネル遮断薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤クラス別（ジヒドロピリジン、ベンゾチゼピン、フェニルアルキルアミン）分析、流通チャネル別（病院、小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のカルシウムチャネル遮断薬市場規模：薬剤クラス別（ジヒドロピリジン、ベンゾチゼピン、フェニルアルキルアミン） ・世界のカルシウムチャネル遮断薬市場規模：流通チャネル別（病院、小売薬局、その他） ・世界のカルシウムチャネル遮断薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Abbvie Inc、Alvogen、Arbor Pharmaceuticals LLC、…） ・市場機会・将来傾向 |
The Calcium Channel Blocker Market is expected to register a CAGR of 5.1 % during the forecast period. The increasing prevalence rate of cardiovascular diseases and changing lifestyle of people is expected to boost the calcium channel blocker market growth. Hypertension often referred as the elevated blood pressure is one of the major causes associated with heart diseases. According to World Health Organization, approximately 1.13 billion of people globally have hypertension. Furthermore, cardiovascular diseases are one of the leading causes of the death and around 17.9 million people died in 2016 due to it. Calcium antagonist are known to be effective against this indication. Thus, the demand has been steadily growing for this market for better management of the cardiovascular diseases. However, the recent years, also observed some cases related to product recalls which restricts the growth of the studied market.
Key Market Trends
Dihydropyridines Segment is Expected to Hold a Major Share in the Calcium Channel Blocker Market
- Though the mechanism of action is similar in all the classes, the pharmacological effects vary. Dihydropyridine is known to exhibit more vasodilation and less negative ionotropic effect in sinoatrial and atrioventricular nodes.
- Also, dihydropyridine calcium channel blockers are majorly prescribed over others in most of the Asia-Pacific region, as reported by the study of Journal of Clinical Hypertension, 2016.
- Moreover, the fourth generation dihydropyridine drug, cilnidipine is considered as an effective treatment against autonomic dysfunction which is a key risk factor for atrial fibrillation. It inhibits L-type calcium as well as N-type of calcium, and are able to dilate efferent and afferent arteriole effectively. Hence, these factors are expected to propel the dihydropyridine segment of calcium Channel blocker market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America expected to hold a major market share in the global calcium Channel blocker market due to changing lifestyle among people and increasing prevalence rate of cardiovascular diseases. The adoption of sedentary lifestyle has serious implications on the health of people and are known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. According to the World Health Organization, around 60% – 85% of people, worldwide, have adopted a sedentary life. According to Centre for Disease Control and Prevention, around 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 US adults & 1 out 5 school student meets the guideline of physical activity. Heart disease is one of the leading causes of death in U.S., at least one person dies every 37 second due to cardiovascular disease, as reported by Centre for Disease Control and Prevention.
Competitive Landscape
The Calcium Channel Blocker Market is fragmented and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc, Alvogen, Abbvie Inc, Exela, Pharma Sciences, LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, Arbor Pharmaceuticals LLC.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cardiovascular Diseases
4.2.2 Changing Lifestyle of People
4.3 Market Restraints
4.3.1 Product Recalls
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Dihydropyridine
5.1.2 Benzothizepine
5.1.3 Phenylalkylamine
5.2 By Distribution Channel
5.2.1 Hospitals
5.2.2 Retail Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc
6.1.2 Alvogen
6.1.3 Arbor Pharmaceuticals LLC
6.1.4 Bausch Health Company Inc.
6.1.5 Covis Pharma BV
6.1.6 Exela Pharma Sciences, LLC
6.1.7 GlaxoSmithKline LLC
6.1.8 Novartis AG
6.1.9 Pfizer Inc
6.1.10 Silvergate Pharmaceuticals Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS